Levy Richard S 4

What Happened

• Richard S. Levy, a director of Kiniksa Pharmaceuticals International, reported a grant of 683 Restricted Share Units (RSUs) that vested immediately on February 1, 2026 and converted into 683 Class A ordinary shares. The Form 4 also reports conversion/disposition entries for 683 derivative shares; all entries show $0 per share (no cash proceeds reported). This was an award/vesting event (not an open-market purchase or sale).

Key Details

• Transaction date: February 1, 2026; Form 4 filed February 4, 2026 (Accession: 0001454983-26-000002).
• Reported items: Grant/Award (A) of 683 RSUs @ $0.00 (acquired); Exercise/Conversion (M) entries showing conversion of 683 RSUs to shares and a corresponding disposition of 683 derivative shares @ $0.00.
• Shares owned after transaction: Not specified in the provided summary.
• Footnotes: F1 — Each RSU represents a contingent right to one Class A ordinary share. F2 — The RSUs vested immediately upon grant on Feb 1, 2026; no expiration date.
• No indication in the provided data that this filing was late.

Context

• RSUs are a form of compensation that convert into shares when they vest; they are not purchases and don’t necessarily signal buying interest. The $0.00 amounts and derivative codes suggest these entries reflect conversion/settlement of RSUs rather than an open-market sale for cash.